Bicara Therapeutics Inc (BCAX) Institutional Ownership Tracker (Q2 2026)

Bicara Therapeutics (ticker BCAX) signed a sublease with Wayfair on August 21, 2026, to rent roughly 35,090 square feet of office space at 10 St. James Avenue in Boston as its new corporate headquarters. Base rent is $105,279 a month, though payments won't begin until nine months after the lease officially starts (which itself hinges on all parties signing off on required consents), and the company put down a $210,540 security deposit. The lease runs no later than September 30, 2028.

Bicara Therapeutics (ticker: BCAX) issued a press release on August 11, 2026, reporting its financial results for the quarter ended June 30, 2026, along with other business updates. The company filed this as an 8-K with the release attached as Exhibit 99.1 for reference; the excerpt doesn't include actual revenue or loss figures. Note that under SEC rules, the release was furnished, not filed, so it isn't treated as a formal filing.

Bicara Therapeutics (BCAX) filed an 8-K on July 23, 2026, disclosing board changes. Kiran Mazumdar-Shaw resigned from the board and a committee effective July 28, with no disagreement cited. The board appointed Jeremy Bender and Christy Oliger as new directors, increasing board size from 9 to 10, and formed a new Launch Readiness Committee chaired by Kate Haviland to guide commercialization strategy. Bender will serve on the Audit Committee, and Oliger on the Nominating and Corporate Governance Committee. Both new directors receive standard non-employee director compensation, including an initial stock option award of 38,950 shares.